Chris Buckner has secured a $6.8 million series A round for his Houston-based esports company thanks to support from a local investment firm. Courtesy of Mainline

A Houston software company is cashing in on the growing esports industry with a multimillion-dollar fundraising round led by a local investor.

Mainline, which specializes in esports tournament software and management, closed its series A at $6.8 million. Houston-based Work America Capital led the round, and Mainline will use the funds to grow its platform, event management customer base, and marketing efforts, as well as to hire developers, marketing, and sales talent.

"The world of esports and gaming is exploding; however, continuity in tournament organization is lacking, keeping the sport from really taking off in other viable and exciting markets," says Chris Buckner, Mainline CEO, in a news release. "Mainline gives brands the tools they need to run powerful esports programs that will evolve the quickly maturing industry to the benefit of players, students, and the greater esports ecosystem."

Mainline, which spun off its sports engagement business earlier this year into a company now called Truss, created a white-labeled tournament platform for esports that's used by various clients across the industry and was instrumental to ESPN's inaugural Collegiate Esports Championship that was hosted in Houston earlier this year.

Work America Capital has supported sports technology in town before — including Houston-based Integrated Bionics, which has developed a GPS- and video-optimized sensor used by athletes around the world.

"As with any industry that takes off like a rocket, problems arise that must be solved through innovation," says Mark Toon, managing partner of Work America Capital, in the release. "Mainline is standardizing, organizing and optimizing the esports industry, paving the way for more players, more teams, more money and bigger, better tournaments."

Mainline is focused on expanding its services as esports continues to grow. According to the release, the total industry revenue for this year is expected to reach $1.1 billion worldwide, and viewership numbers have jumped from 335 million to 454 million in just two years.

"The strategic vision of Mainline puts them in the driver's seat with a consistent platform across amateur, collegiate and professional competitions," says Toon. "Given Mainline's partnerships and customers, they have paved a way to grow quickly across all sports and into other markets. We are excited to dedicate our time, resources and capital to the company."


Mainline has created a white-labeled software for esports gaming and tournaments. Courtesy of Mainline

The Cannon's new building is 88 percent leased and ready for move in. Courtesy of The Cannon

Photos: The Cannon unveils its 120,000-square-foot startup hub in West Houston

Homecoming

The Cannon is finally getting to move its 150 startups and partners into its 120,000-square-foot campus in West Houston.

The original plan was to open in March, but construction, which began in April 2018, faced a series of setbacks due to weather. Current grand opening celebration plans are expected to be in September.

The flagship building is just the first step developing the campus, which is dubbed the Founders District.

"Our team has worked tirelessly to build this community over the past eighteen months, and we are incredibly proud to see our vision coming to life with the completion of this building," says The Cannon's CEO Lawson Gow in a news release. "The work isn't over though, and The Cannon will continue to grow our network of resources and locations to cater to the needs of Houston's growing entrepreneurial community." (Gow is the son of David Gow, owner of InnovationMap's parent company Gow Media.)

The building is currently 88 percent leased. Cannon Ventures, the company's investor group, will operate out of the new building, as will Capital Factory's Houston outpost. Austin-based Capital Factory, a statewide startup accelerator announced it would have its Houston operations at The Cannon in May. Since then, the company hired two Houston-based employees to run the programming.

According to the release, The Cannon will continue to grow its community relations for a "full suite" of partners. Houston-based investment fund Work America Capital, which led The Cannon's initial fundraising round, will also be joining The Cannon's community in the new building.

"It has been incredible to watch The Cannon's exceptional growth from inception two years ago to the vibrant community they've built today," says Mark Toon, managing partner of Work America Capital, in the release. "We can't wait to see the progress first-hand as The Cannon continues to establish themselves as a leader in building entrepreneurial communities."

The Cannon previously operated out of a 20,000-square-foot adjacent building called "The Waiting Room," which will be torn down and the space will be used as a part of the bigger Founders District plan.

The Cannon's new space will feature:

  • A 16-TV video wall
  • Outdoor courtyard
  • Movie theater
  • Snacks, coffee, and beer
  • Office needs, such as printers, scanners, and mail services
  • Showers
  • 24/7 accessibility
  • Professional and social events are organized on an ongoing basis for the community
  • Private event hosting for both members and non-members

Spacious setting

Courtesy of The Cannon

The Cannon is currently 88 percent leased.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

New Houston biotech co. lands $30M for pulmonary fibrosis drug

drug money

Most of us can claim a scar or two on our bodies. But when scarring develops inside the body, it’s known as a fibrotic disorder. A freshly launched Houston company, Oorja Bio Inc., is working on a treatment that can help to repair cells and reduce the damage wrought by the growth of fibrotic tissue in patients.

Late last month, Oorja Bio hit the scene with a pair of big announcements. Not only has the company raised a $30 million Series A thanks to founding investor California-based Westlake BioPartners, but it has also already paved the way for a Phase 2 study to take place this year.

Oorja Bio received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), allowing the company to test its treatment in patients with idiopathic pulmonary fibrosis (IPF), a scarring of the lung tissue. IPF affects more than 150,000 adults in the United States and can result in a range of symptoms from shortness of breath to organ failure and death as it progresses.

Oorja Bio’s lead drug candidate, ORJ-001, was shown in a Phase 1 in-human trial to demonstrate “therapeutically relevant exposure and favorable tolerability” in 64 healthy adult volunteers in whom it was administered daily or weekly, according to a news release. Pre-clinical studies of ORJ-001 showed durable target tissue engagement and biomarker activity in bleomycin-induced lung fibrosis.

Administered subcutaneously, ORJ-001 is intended to improve and even restore function in cells that can reduce the signaling that causes IPF. It stops advancement of IPF and also allows for tissue repair. Currently available treatments for the disease can slow the development of IPF down, but do not address the declining lung function that’s inherent in its progression.

“The clinical and preclinical results from our studies to date give us confidence that ORJ-001 represents a novel treatment approach with the potential to repair and reverse fibrosis and modify disease progression in IPF,” Dr. Janethe Pena, CMO of Oorja Bio, said in the release.

“Our team is energized to deliver on our goal of redefining the future of fibrotic diseases, beginning with ORJ-001,” CEO and founder Sujay Kango added. “As we advance ORJ-001 in the clinic, we are embracing the paradigm shift in our biological understanding of IPF pathology that aligns with the central role of the alveolar epithelium. ORJ-001 was designed with this biology in mind and may provide, for the first time, a therapeutic intervention that repairs and reverses fibrosis and promotes disease modification.”

Most patients live only three to five years following their IPF diagnosis. Soon, ORJ-001 and Oorja Bio could give them a fighting chance.

Axiom Space tops $525M in oversubscribed round, announces Swiss subsidiary

funding boost

Axiom Space tacked on an additional $175 million to a previously announced capital raise, bringing the oversubscribed round to a total of more than $525 million.

Axiom shared in February that it had secured $350 million in a financing round led by Type One Ventures and Qatar Investment Authority. In the latest release from the company, Axiom reports that Japan-based MUFG Bank Ltd. joined the round as a new investor, in addition to continued participation from existing backers.

The funding will go toward developing the company's commercial space station, known as Axiom Station, and the production of its Axiom Extravehicular Mobility Unit (AxEMU) under its NASA spacesuit contract.

“Investor interest in this round outpaced what we set out to raise, which speaks to the moment we’re in,” Jonathan Cirtain, CEO and president of Axiom Space, said in the news release. “Our partners see what is possible in low-Earth orbit, and they see who is positioned to lead it.”

Axiom announced last month that it planned to open a Japanese subsidiary July 1. Earlier this week, it also shared plans to establish Axiom Space Switzerland, a wholly owned subsidiary based in Lucerne that is also expected to begin operations this summer.

The Switzerland subsidiary aims to establish Axiom's presence in Europe and help it partner with the European Space Agency and other space organizations and companies on the continent.

“Europe is a founding leader in the creation of the commercial space economy, and Switzerland is uniquely positioned to convene the government agencies, research institutions, and industrial entities that will shape its next decade,” Cirtain added in a separate release. “Axiom Space Switzerland facilitates the scaling of development and deployment of the infrastructure that will succeed the International Space Station.”

Texas cashes in among 10 best U.S. state economies in 2026 report

State Economics

A new study gauging the success or decline in economic performance in every state has revealed Texas' economy remains stable in 2026 after it dropped out of the top five to No. 8 last year.

Texas boasts the No. 8 best state economy in the U.S. this year, according to WalletHub's annual "Best & Worst State Economies" report. The personal finance website's analysts ranked all 50 states and the District of Columbia across 28 relevant metrics to measure each state's economic activity and health status, and its "innovation potential."

Notably, Texas leads the nation for the most exports per capita in the U.S. in a five-way tie with Louisiana, Kentucky, North Dakota, and Indiana. Across the study's three main categories, Texas ranked highly for its economic activity (No. 7) and economic health (No. 11), and the state's "innovation potential" rank is the 24th best in the nation.

This is how WalletHub ranked Texas' economic performance, where No. 1 is considered the best and No. 25 is considered average:
  • No. 6 – Change in non-farm payrolls
  • No. 8 – Change in GDP
  • No. 8 – Startup activity
  • No. 11 – Annual median household income
  • No. 18 – Government surplus/deficit per capita
  • No. 21 – Percentage of jobs in high-tech industries
  • No. 30 – Unemployment rate
WalletHub previously ranked Texas one of the top three states to start a business in 2026, with Houston earning its own entrepreneurial acclaim in separate rankings of the best big cities for new businesses and for starting a career.

"U.S. economic growth depends heavily on the performance of individual states, and some contribute more than others," the report's author wrote. "For example, California, Texas, New York and Florida have economies so large that if they were countries, they would rank in the top 20 in the world."

The five states with the worst state economies in 2026 are Rhode Island (No. 47), Maine (No. 48), Louisana (No. 49), Kentucky (No. 50), and West Virginia (No. 51).

The top 10 best state economies for 2026 are:

  • No. 1 – Massachusetts
  • No. 2 – Washington
  • No. 3 – Utah
  • No. 4 – California
  • No. 5 – Delaware
  • No. 6 – North Carolina
  • No. 7 – New York
  • No. 8 – Texas
  • No. 9 – Colorado
  • No. 10 – Florida

---

This article originally appeared on CultureMap.com.